No CrossRef data available.
Article contents
Heterogeneous effectiveness patterns of amisulpride in chinese patients with schizophrenia: A cluster analysis of ESCAPE study
Published online by Cambridge University Press: 23 March 2020
Abstract
Rare research was reported about assessing the effectiveness and safety of amisulpride in Chinese patients with schizophrenia before we performed the ESCAPE, a multicenter, single-arm, phase IV study (NCT01795183). This study is a cluster analysis of ESCAPE study.
To identify the effectiveness patterns of amisulpride in Chinese patients with schizophrenia.
To examine baseline characteristics of patients as potential predictors of effectiveness.
Time-series cluster analysis was performed to identify effectiveness trajectories bases on Positive and Negative Syndrome Scale (PANSS) scores in Chinese patients with schizophrenia received amisulpride for 8 weeks. Baseline characteristics of patients were examined.
Overall, 295 patients were included for efficacy analysis. Four response trajectories based on positive PANSS were identified (Figure 1): (1) rapid response (cluster 1); (2) gradual response (cluster 2); (3) sustained low level (cluster 3); (4) poor response (cluster 4). Age in cluster 4 was significantly higher than that in cluster 1 and cluster 3 (Table 1, P = 0.0025 and 0.0032, respectively). Similarly, four response trajectories based on negative PANSS were generated (Figure 2): (1) rapid response (cluster 1); (2) gradual response (cluster 2); (3) poor response with moderate PANSS (cluster 3); (4) poor response with high PANSS (cluster 4). Male to female ratio in cluster 1 was significantly lower than that in cluster 2 and cluster 3 (Table 2, P = 0.0042 and 0.0208, respectively).
For the first time, we obtained effectiveness patterns of amisulpride-treated Chinese patients. Age and gender may be predictors of effectiveness.
This study is being funded by Sanofi (China) Investment Co., Ltd.
- Type
- e-Poster Viewing: Schizophrenia and other psychotic disorders
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s819 - s820
- Copyright
- Copyright © European Psychiatric Association 2017
Comments
No Comments have been published for this article.